DRRX beat EPS expectations by 30.80%
Aug 13, 2024, 8:32 PM
0.00%
What does DRRX do
DURECT Corp., headquartered in Cupertino, California, specializes in developing investigational therapies like DUR-928 for metabolic and lipid disorders and acute organ injuries, and has other products like POSIMIR and PERSERIS. The company, which employs 72 people and went public in 2000, is conducting a Phase IIb AHFIRM study on larsucosterol for treating alcohol-associated hepatitis.
Durect (DRRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Durect's actual EPS was -$0.12, beating the estimate of -$0.17 per share, resulting in a 30.80% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.